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Background: Adjuvant and salvage radiotherapy of the prostate bed are established treatment options for prostate
cancer. While the benefit of an additional radiotherapy of the pelvic lymph nodes is still under debate, the PLATIN
3 prospective phase II clinical trial was initiated to substantiate toxicity data on postoperative IMRT of the pelvic
lymph nodes and the prostate bed.
Methods: From 2009 to 2011, 40 patients with high-risk prostate cancer after prostatectomy with pT3 R0/1 M0 or
pT2 R1 M0 or a PSA recurrence and either > 20% risk of lymph node involvement and inadequate lymphadenectomy or
pN +were enrolled. Patients received two months of antihormonal treatment (AT) before radiotherapy. AT continuation
was mandatory during radiotherapy and was recommended for another two years. IMRT of the pelvic lymph nodes
(51.0 Gy) with a simultaneous integrated boost to the prostate bed (68.0 Gy) was performed in 34 fractions. PSA level,
prostate-related symptoms and quality of life were assessed at regular intervals for 24 months.
Results: Of the 40 patients enrolled, 39 finished treatment as planned. Overall acute toxicity rates were low and no
acute grade 3/4 toxicity occurred. Only 22.5% of patients experienced acute grade 2 gastrointestinal (GI) and
genitourinary (GU) toxicity. During follow-up, 10.0% late grade 2 GI and 5.0% late grade 2 GU toxicity occurred,
and one patient developed late grade 3 proctitis and enteritis. After a median observation time of 24 months the
PLATIN 3 trial has shown in 97.5% of all patients sufficient safety and thus met its prospectively defined aims. After a
median of 24 months, 34/38 patients were free of a PSA recurrence.
Conclusions: Postoperative whole-pelvis IMRT with an integrated boost to the prostate bed can be performed safely
and without excessive toxicity.
Trial registration: Trial Numbers: ARO 2009–05, ClinicalTrials.gov: NCT01903408.
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Postoperative radiotherapy of the prostate bed (PBRT) is
a standard procedure for patients with an increased risk
of local recurrence. Three prospective randomised trials
demonstrated that PBRT significantly increases the bio-
chemical recurrence free survival (BFS) compared to
observation: EORTC 22911 [1], SWOG 8794 [2] and
ARO 96–02 [3]. Whether patients benefit from the inclu-
sion of the pelvic lymph nodes in the radiooncological* Correspondence: sonja.krause@med.uni-heidelberg.de
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reproduction in any medium, provided the ortreatment volume (whole pelvis radiotherapy, WPRT) is
still subject to debate even in the setting of definitive radio-
therapy [4,5]. In the adjuvant setting, data on radiotherapy
of the pelvic lymph nodes is even more limited. Spiotto
et al. [6] performed a retrospective analysis of 160 patients
after prostatectomy who obtained either irradiation of the
prostate bed or WPRT as adjuvant or salvage radiotherapy.
Of these, 114 patients were at high risk of lymph node in-
volvement (Gleason score ≥ 8, initial PSA > 20 ng/ml, ECE,
SVI or pN+) and received either WPRT (n = 72) or treat-
ment of the prostate bed (n = 42) with or without a short
course of neoadjuvant and concurrent total androgen sup-
pression. Five-year-BFS was significantly higher in theral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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benefit could only be shown for high risk patients
(5 year BFS 47% vs. 21%, for WPRT vs. PBRT, respectively).
Likewise, Briganti et al. showed in a matched-pair analysis
of 703 pT2-4 pN + patients that the combination of andro-
gen deprivation and radiotherapy prolonged cause-specific
and overall survival compared to androgen deprivation
alone [7]. In contrast, a retrospective cohort study of 247
patients comparing WPRT vs. PBRT that excluded patients
under androgen suppression only demonstrated a benefit
regarding biochemical control for patients with a pretreat-
ment PSA ≥ 0.4 ng/ml [8].
The PLATIN (Prostate and Lymph Node Irradiation with
Integrated-Boost-IMRT after Neoadjuvant Antihormonal
Treatment) phase II trial was initiated in 2009 to investi-
gate safety and feasibility of an irradiation of the pelvic
lymph nodes simultaneously with an integrated boost to
either the prostate (PLATIN 1), the prostate and macro-
scopic nodes (PLATIN 2), the prostate bed (PLATIN 3),
the prostate bed and macroscopic nodes (PLATIN 4) or to
macroscopic nodes in patients that had received PBRT be-
fore (PLATIN 5). Secondary objectives were a detailed
characterisation of the toxicity profiles of the respective
treatments and the evaluation of quality of life.
This article reports first safety and efficacy data of the
intensity-modulated radiotherapy (IMRT) treatment of
the pelvic lymph nodes with a simultaneous boost to the
prostate bed (PLATIN 3).
Methods
Before trial initiation, ethical consent was obtained from
the ethics committee of the University of Heidelberg,
Germany (Medical Faculty). All patients gave written
informed consent before inclusion in the trial.
From May 2009 to May 2011, 40 patients were en-
rolled prospectively in the PLATIN 3 trial. Eligibility
criteria were a resected prostate carcinoma with pT3
R0/1 or pT2 R1 or with a postoperative PSA recurrence
(defined as three consecutive PSA rises above the nadir).
Additionally, pN + disease or an estimated risk of lymph
node involvement > 20% according to the Roach formula
[9] with inadequate nodal dissection (<10) were required.
Patients received at least two months of neoadjuvant
AT which was continued during radiotherapy in all cases.
Continuation was recommended for two years after
irradiation.
For treatment planning, CT scans with 3 mm slice
thickness at full bladder and empty rectum were per-
formed. PTV-P (planning target volume - prostate bed)
comprised the prostate bed including the bottom of the
bladder and the anterior rectal wall with a margin of
0.5 cm. PTV-L (planning target volume - lymph nodes)
included the obturatory, internal and external iliac, com-
mon iliac and presacral (down to S3) nodes [10] with a0.5 mm margin. Pararectal nodes were not included in
the PTV-L. Inverse treatment planning was performed
using the Tomotherapy® Treatment Planning Software.
A total dose of 51.0 Gy was prescribed to 95% of PTV-L
with a simultaneous integrated boost of 68.0 Gy to 95%
of PTV-P in 34 fractions. The dose prescription to the
lymph nodes of 51 Gy in 1.5 Gy fractions is biologically
equivalent to 43.7 Gy, assuming an α/β of 1.5 Gy for
prostate cancer, and 48.2 Gy, assuming an α/β of 7 Gy
for small bowel. Treatment with Helical Tomotherapy
was performed with full bladder and empty rectum
under daily image guidance.
Prostate-specific symptoms and treatment toxicity,
using the criteria of the NCI CTC AE version 3.0, were
recorded before treatment, weekly during treatment, at
the end of treatment, and at 2.5, 6, 12, 18 and 24 months
after start of treatment. For calculation of toxicity rates,
only the patients with available data at the respective
time points were considered. Cumulative GI toxicity was
defined as the cumulative incidence of diarrhea, enteritis
and proctitis. To facilitate comparison with other publi-
cations, only cystitis was included in the calculation of
cumulative genitourinary toxicity, as most scoring sys-
tems do not include incontinence and erectile dysfunc-
tion. Nevertheless, incontinence and erectile dysfunction
were recorded (according to NCI CTC AE version 3.0).
Cumulative toxicity rates were calculated considering all
40 patients enrolled in the trial.
Quality of life was assessed using the EORTC QLQ-
C30 questionnaire before and at the end of treatment
and at 6, 12 and 24 months.
PSA levels were measured before the start of treat-
ment and then every three months, starting from week
10. Biochemical failure was established when at three
subsequent time points with a minimum interval of
4 weeks PSA levels increased continuously from the lowest
measured PSA.
As primary endpoint, the safe treatment application
rate (STR) was chosen. STR was defined as the pro-
portion of patients receiving treatment as planned
and without grade 3–4 toxicity and calculated as the
ratio of the number of patients fulfilling this criteria
divided by the size of the intent-to-treat (ITT) popula-
tion. The ITT population consisted of all patients giv-
ing informed consent, fulfilling the inclusion/exclusion
criteria and receiving planned treatment for a mini-
mum of 4 weeks after initiation. Based on a one-stage
phase II type design, STR of 80% (null-hypothesis
STR ≤ 80%) was tested against the alternative of be-
ing at least as large as 95% in a one-stage phase-II
type design using the exact Binomial test at the sig-
nificance level of 0.1% with a power of 90%. The null
hypothesis would be rejected when STR would be at
least 87.7%.
Table 1 Average dose exposure to the rectum, small
bowel and bladder
Rectum
Maximum anterior rectal wall 71.4 Gy ± 1.1 Gy
V40 Gy 41.0% ± 13.8% / 41 ml ± 14 ml
V60 Gy 9.5% ± 5.7% / 10 ml ± 6 ml
V70 Gy 1.0% ± 1.5% / 1 ml ± 1 ml
Small bowel
Maximum 53.1 Gy ± 1.2 Gy
V20 Gy 42.1% ± 15.2% / 672 ml ± 243 ml
V40 Gy 10.3% ± 6.3% / 164 ml ± 101 ml
Bladder
V40 Gy 40.9% ± 8.8% / 125 ml ± 27 ml
V60 Gy 13.2% ± 8.2% / 40 ml ± 25 ml
V70 Gy 3.5% ± 3.6% / 11 ml ± 11 ml
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Patient characteristics
Among the 40 eligible patients (identical with the ITT
population), median follow-up was 24 months (range:
15–24 months). Median age at inclusion was 68 years
(range: 46–75 years); all patients had high-risk disease
according to the D‘Amico risk categories [11] based on
preoperative staging. The majority of patients (50%) had
Gleason 9 tumors, while 20% and 30% were staged as
Gleason 8 and 7, respectively. There were 23 patients
with pN+ disease and 17 patients with an estimated risk
of lymph node involvement > 20% and inadequate lymph-
adenectomy. Radiotherapy was performed as adjuvant
treatment in 30 patients and 10 patients received salvage
radiotherapy for a PSA recurrence. Median time between
prostatectomy and radiotherapy was 7 months for adju-
vant treatment (range 2–17 months) and 14 months for
salvage radiotherapy (range 7–56 months). Median PSA
before the start of AT and radiotherapy was 0.4 ng/ml in
the adjuvant setting and 0.19 ng/ml in patients receiving
salvage radiotherapy.
Treatment was fully completed by 39/40 patiens. One
patient developed diarrhea which was objectively scored
as grade 2. However, the patient could not cope with the
symptoms, refused supportive medication and further
consultation and eventually refused treatment continu-
ation after 22 fractions. Another patient developed low
blood sodium during radiotherapy, was subsequently
diagnosed with metastasised small lung cancer after
finishing radiotherapy and was lost to follow-up shortly
thereafter.
Treatment characteristics
Average beam on time was 7:59 min (± 1:00 min). The
intended target coverage could be met, as 95% of the
PTV-P received 68.0 ± 0.67 Gy (median dose: 70.12 ±
0.62 Gy) and 95% of the PTV-L received 50.27 ± 0.43 Gy
(median dose: 52.97 ± 0.73 Gy).
Plan quality in terms of organ at risk sparing is shown in
Table 1. On average, the anterior rectal wall received a
maximum dose of 71.4 Gy (range: 67.0 Gy - 71.9 Gy). Only
small volumes of the rectum received doses ≥ 60 Gy (9.5%)
and ≥ 70 Gy (1.0%), respectively. Dose to the small bowel
could be kept at low levels with 10.3% of the small bowel
exposed to ≥ 40 Gy and a maximum dose of 53.1 Gy. Most
of the bladder could be spared from high dose exposure,
with 3.5% of the bladder receiving ≥ 70 Gy.
Treatment safety
After a median observation time of 24 months one
patient terminated treatment prematurely but no patient
showed acute toxicity ≥ grade 3. Therefore at this stage
the PLATIN 3 trial has shown a promising STR of 97.5%
(39/40) and has met the prospectively defined statisticalcriterion of a successful treatment with an STR of at least
87.7%.
Gastrointestinal toxicity
Cumulative incidence of acute gastrointestinal (GI) toxicity
was 67.5% (grade 1) and 22.5% (grade 2), respectively,
but no acute grade 3/4 GI toxicity occurred. Investiga-
tion of different GI symptoms showed that at the end
of treatment, the rates of grade 1 (< 4 stools increase
over baseline) and 2 (4–6 stools increase over baseline)
acute diarrhoea were 28.2% and 2.6%, respectively, while
17.9% of patients reported rectal discomfort not requir-
ing intervention (proctitis grade 1) and 12.8% had symp-
toms of rectal discomfort or passing of mucus or blood
that required medical intervention (grade 2). Enteritis
grade 1 (asymptomatic, not requiring intervention) oc-
curred in 15.4%.
Cumulative late GI toxicity was 7.5% (grade 1), 10.0%
(grade 2) and 5.0% (grade 3), respectively. No patient
suffered from late diarrhea of any grade, and only one
patient experienced late proctitis and enteritis grade 3 at
18 months of follow-up (see Table 2).
Genitourinary toxicity
Genitourinary (GU) toxicity was low with a cumulative
incidence of acute GU toxicity grade 1 and 2 in 22.5% of
patients each. Cumulative incidence of late GU toxicity
was 22.5% (grade 1) and 5.0% (grade 2), respectively. No
patient developed acute or late cystitis grade 3/4. At the
end of treatment, mild acute cystitis was reported by
25.6% (grade 1) and 20.5% (grade 2) (see Table 3).
A substantial proportion of patients (62.5%) experi-
enced urinary stress incontinence before the start of
radiotherapy: grade 1 stress incontinence (occasional, no
pads necessary) was present in 47.5% of patients, 15.0%
Table 2 Acute and late gastrointestinal toxicity
Diarrhea Grade 1 Grade 2 Grade 3 Grade 4
End of RT 28.2% 2.6% - -
13 weeks 7.9% - - -
6 months - 2.7% - -
12 months 2.7% - - -
18 months - - - -
24 months - - - -
Enteritis Grade 1 Grade 2 Grade 3 Grade 4
End of RT 15.4% - - -
13 weeks - 7.9% - -
6 months - 5.4% - -
12 months - - - -
18 months 31.% - - -
24 months - 4.5% - -
Proctitis Grade 1 Grade 2 Grade 3 Grade 4
End of RT 17.9% 12.8% - -
13 weeks 10.5% - - -
6 months 2.7% 2.7% - -
12 months - - - -
18 months - - 3.1% -
24 months - - - -
Diarrhea: CTC AE grade 1 = increase < 4 stools per day over baseline;
grade 2 = increase 4-6 stools per day; grade 3 = increase ≥ 7 stools per day or
incontinence or hospitalisation or limiting self care ADL; grade 4 = life-threatening
consequences, urgent intervention indicated.
Enteritis: CTC AE grade 1 = asymptomatic; grade 2 = abdominal pain, mucus or
blood in stool; grade 3 = severe or persistent abdominal pain, fever, ileus,
peritoneal signs; grade 4 = life-threatening consequences, urgent
intervention indicated.
Proctitis: CTC AE grade 1 = rectal discomfort, intervention not indicated;
grade 2 = symptoms (e.g. rectal discomfort, passing blood or mucus), medical
intervention, limiting instrumental ADL; grade 3 = severe symptoms, fecal
urgency or stool incontinence, limiting self care ADL; grade 4 = life-threatening
consequences, urgent intervention indicated.
Table 4 Erectile function
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Severity of stress incontince varied during follow-up:
Twelve months after treatment, 35.1% reported grade 1
and 29.7% grade 2 incontinence, respectively. After
24 months, grade 1 stress incontinence was present in
14.3% of patients and grade 2 in 19.1% of patients.Table 3 Acute and late cystitis
Cystitis Grade 1 Grade 2 Grade 3 Grade 4
End of RT 25.6% 20.5% - -
13 weeks 2.6% 7.9% - -
6 months 5.4% 8.1% - -
12 months 2.7% 2.7% - -
18 months 16.1% - - -
24 months - 4.5% - -
Cystitis: CTC AE grade 1 = asymptomatic; grade 2 = frequency with dysuria,
macroscopic hematuria; grade 3 = transfusion, IV pain medications, bladder
irrigation indicated; grade 4 = catastrophic bleeding, major non-elective
intervention indicated.Urge incontinence increased after treatment from
12.5% and 2.5% of patients suffering from grade 1
and 2 incontinence before treatment to 21.6% and
5.4% after 12 months and 14.3% and 4.8% after 24 months,
respectively.
Two patients required urinary catheterisation during
treatment and one during follow-up due to urinary re-
tention. At 24 months of follow-up, all patients that had
completed follow-up were catheter-free.
Directly after surgery and even before the start of AT,
a large proportion of patients (85%) reported a complete
loss of erectile function. This percentage increased dur-
ing the course of treatment and follow-up to 95% (see
Table 4). Before the start of AT, 21% of patients had
experienced no change in libido while 28.2% reported a
complete loss of libido. The latter proportion increased
with the duration of AT up to 77% after 24 months.
Quality of life
Overall health as assessed by the “Global Health Score”
of the EORTC QLQ-C30 questionnaire remained almost
unchanged at the three investigation times 6, 12 and
24 months compared to baseline with and average score
of 67.1 before radiotherapy and 73.2 after 24 months.
Scores were on a similar level as the EORTC reference
value (68.4) of prostate cancer patients over all disease
stages. Similarly, the other scores involving physical,
emotional, cognitive and social functioning as well as
role functioning were constant over the course of treat-
ment and observation period (data not shown).
Biochemical control and survival
During follow-up, four patients experienced PSA recur-
rences, two of which were under AT at that time. In one
patient, PSA recurrence coincided with the diagnosis of
bone metastases; in the other three patients, the site of
recurrence could not be determined. At the time of ana-
lysis, 19 patients still received AT. Average duration of
AT was 11.5 months for the 38 patients remaining in theErectile function Grade 0 Grade 1 Grade 2 Grade 3
Before AT 2.6% 7.7% 5.1% 84.6%
After 2 months of AT - 2.6 % 5.1% 92.3%
End of RT 2.6% 2.6% 12.8% 82.1%
13 weeks 2.6% 7.9% 10.5% 78.9%
6 months 2.7% 5.4% 8.1% 83.8%
12 months 2.8% 2.8% 8.3% 86.1%
18 months - - 9.7% 90.3%
24 months - - 4.8% 95.2%
Erectile function: CTC AE grade 1 = erectile dysfunction; grade 2 = decrease in
erectile function (frequency/rigidity of erections) but erectile aids not
indicated; grade 2 = decrease in erectile function, but erectile aids not helpful.
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alive at a median of 24 months after start of treatment.
One patient had developed acute myeloid leucemia
(AML) at 14 months of follow up and had eventually
died of the disease.
Discussion
While the role of adjuvant radiotherapy of the whole
pelvis remains controversial, this prospective trial shows
good tolerability of an IMRT-based treatment of the
pelvic lymph nodes. At the point of analysis, 34 of 38
patients were free of biochemical recurrence. For a reli-
able evaluation of efficacy, however, a median follow-up
of 24 months is not sufficient.
Helical IMRT of the pelvic lymph nodes with a simul-
taneous integrated boost to the prostate bed could be
performed in satisfying speed with an average treatment
time of 8 min.
In two patients, a secondary malignancy (small cell
lung cancer and AML) was diagnosed during follow-up.
Since both occurred within 12 months after radiother-
apy, the probability for them being radiation-induced is
low.
In the present trial, no patient developed acute or late
grade 3/4 genitourinary toxicity or acute grade 4 gastro-
intestinal toxicity. Only one patient experienced late
grade 3 proctitis and enteritis 18 months after the start
of treatment. This patient had a history of resection of
rectal cancer with a subsequent anal stenosis requiring
multiple treatments 20 years prior to prostate cancer
treatment. During follow-up, a peak (5/31 patients) of
grade 1 cystitis occurred at 18 months, which had sub-
sided in 2 of 3 patients at the next visit.
Although the evaluation of erectile function based on
patient-reported data is prone to reporting bias, weTable 5 Publications on acute toxicity of radiotherapy of the
Acut
GI
Bellavita et al. [13] 3D-CRT prostate bed 66.6 Gy 48.9% (G
Current trial IMRT WPRT 51 Gy + boost prostate bed
68 Gy
67.5%
Alongi et al. [14] IMRT WPRT 50.6 Gy + boost prostate bed
70–72.5 Gy
-
Deville et al. [15] IMRT WPRT 45 Gy Gy + boost prostate bed
70.2 Gy
31%
Alongi et al. [14] 3D-CRT WPRT 50.1 Gy + boost prostate bed 72.1 Gy -
Aizer et al. [16] 3D-CRT WPRT 45 Gy + IMRT boost prostate 75.6 Gy 75%
Roach et al. [4] 3D-CRT WPRT 45 Gy + boost prostate 70.2 Gy -
Liu et al. [17] 2D WPRT 45 Gy + boost prostate 72 Gy 12.2%
Published data on acute toxicity of adjuvant 3D conformal radiotherapy (3D-CRT) o
(IMRT) of the whole pelvis (WPRT) with a boost to the prostate bed (bold print) and
bed (italic print). (GI = gastrointestinal, GU = genitourinary).could detect only a small effect of postoperative radio-
therapy on erectile function. However, compared to lit-
erature, a large proportion of patients in our trial (85%)
initially reported complete loss of erectile function,
probably due to the fact that all patients had high-risk
disease and consecutively extensive surgery.
One limitation of this trial is the follow-up of currently
two years. Further observation time is needed for a final
evaluation of late toxicity, since especially late GU tox-
icity can occur up to ten years after treatment. In this
trial, no direct comparison to standard irradiation of the
prostate bed was performed. For further evaluation of
clinical efficacy, a randomised prospective trial with a far
larger number of patients and a more homogeneous
patient group is warranted.
In addition, since a conventional fractionation was
intended for the prostate bed, the daily dose given to
pelvic lymphatic drainage (1.5 Gy) was lower than con-
ventional fractionation. This might have a negative effect
on the efficacy of WPRT.
Comparison of our toxicity data to trials on postopera-
tive radiotherapy of the prostate bed [1-3] is complicated
by the fact that different scoring systems were used and
the applied dose, the manner of toxicity reporting and
the follow-up time vary between trials. Yet, our results
compare favourably to the treatment of the prostate bed
alone (see Tables 5 and 6): First of all, like in all three
trials, we saw no grade 4 acute or late toxicity. The
EORTC trial [1,12] reported a 5-year cumulative inci-
dence of 4.2% grade 3 toxicity. In the ARO trial [3], the
rate of grade 3 toxicity was 0.3%. With 1/40 patients
with grade 3 enteritis and proctitis our results are con-
curring with that data. A more recent publication on
postoperative prostate bed irradiation [13] also stated
similar toxicity: Among 182 patients treated with aprostate bed with or without pelvic irradiation
e grade 1 Acute grade 2 Acute grade 3 Acute grade 4
GU GI GU GI GU GI GU
1/2) - - - 1.1% - 0% 0%
22.5% 22.5% 22.5% 0% 0% 0% 0%
- 3.3% 6.6% 0% 0% 0% 0%
67% 61% 22% 0% 0% 0% 0%
- 8.6% 12.3% 0% 0% 0% 0%
44.1% 17.6% 33.8% 1.5% 10.3% 0% 0%
- - - 2.6% (G3/4) 3.9% (G3/4) 0% 0%
10.9% 1.3% 3.8% 0.6% 0.6% 0% -
f the prostate bed (regular print), adjuvant intensity-modulated radiotherapy
definitive or adjuvant 3D-CRT WPRT with a boost to the prostate or prostate
Table 6 Publications on late toxicity of radiotherapy of the prostate bed with or without pelvic irradiation
Median
follow-up
Late grade 1 Late grade 2 Late grade 3 Late grade 4
GI GU GI GU GI GU GI GU
Bolla et al. [1] 3D-CRT prostate bed 66.0 Gy 60 months - - - - 4.2% 0% 0%
Bolla et al. [12] 3D-CRT prostate bed 66.0 Gy 127 months - - - - 5.3% 0% 0%
Wiegel et al. [3] 3D-CRT prostate bed 66.60 Gy 54 months - - 1.4% 2.0% - 0.5% 0% 0%
Bellavita et al. [13] 3D-CRT prostate bed 66.6 Gy 56 months 7.1% (G1/2) 9.9% (G1/2) - - 0.5% 5.5% 0% 0%
Ost et al. [18] IMRT/3D-CRT prostate bed 69.1 Gy 60 months ∼ 28% ∼ 34% ∼ 5% ∼ 17% < 1% 10% 0% 0%
Current trial IMRT WPRT 51 Gy + boost
prostate bed 68 Gy
24 months 7.5% 22.5% 10.0% 5.0% 5.0% 0% 0% 0%
Deville et al. [15] IMRT WPRT 45 Gy Gy + boost
prostate bed 70.2 Gy
26 months 11% 50% 3% 17% 0% 11% 0% 0%
Aizer et al. [16] 3D-CRT WPRT 45 Gy + IMRT boost
prostate 75.6 Gy
30 months 2.9% 1.5% 4.4% 1.5% 1.5% 0% 0% 0%
Roach et al. [4] 3D-CRT WPRT 45 Gy + boost
prostate 70.2 Gy
- - - - - 4.3% (G3/4) 3.0% (G3/4) - -
Published data on late toxicity of adjuvant 3D conformal radiotherapy (3D-CRT) of the prostate bed (regular print), adjuvant intensity-modulated radiotherapy
(IMRT) of the whole pelvis (WPRT) with a boost to the prostate bed (bold print) and definitive or adjuvant 3D-CRT WPRT with a boost to the prostate or prostate
bed (italic print). (GI = gastrointestinal, GU = genitourinary).
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CRT, acute GU and GI toxicity occurred in 39.6% and
50% of patients, respectively. Only two patients experi-
enced acute grade 3 GI toxicity. Late GU and GI toxic-
ities were seen in 15.4% and 7.7%, with one grade 3 GI
side effect and 10 GU toxicities.
Although data on the benefit of WPRT is sparse, many
radiation oncology centers electively treat the pelvic lymph
nodes because of publications on surgical lymph node sam-
pling and nanoparticle-enhanced MRI studies that revealed
a high proportion of occult lymph node metastases [19,20].
In contrast, other centers avoid WPRT in because of con-
cerns about excessive toxicity.
In recent years, first clinical trials [14,15] provided tox-
icity data on postoperative IMRT treatment of the pelvic
lymph nodes (see Tables 5 and 6). Alongi et al. [14] showed
for the first time that acute WPRT toxicity could be low-
ered substantially with the use of IMRT. Among 172 pa-
tients that received postoperative WPRT with either a 3D
conformal technique or IMRT, acute ≥ grade 2 GU and GI
toxicity was significantly lower in the IMRT group. In their
series of 67 patients receiving either 45 Gy IMRT to the
whole pelvis and a 70.2 Gy boost to the prostate bed or
prostate bed irradiation alone, Deville et al. [15] described
an increase in acute grade 2 GI toxicity in the WPRTgroup.
However, acute ≥ grade 2 GU toxicity as well as late ≥ grade
2 GI or GU toxicity was not increased with WPRT.
The currently recruiting RTOG 0534 trial will provide
randomized data on postoperative WPRT: patients with
pT2-3 pN0/Nx R0/1 tumors Gleason ≤ 9 with a rising
PSA (≥ 0.1 - < 2.0 ng/ml) after prostatectomy receive
neoadjuvant and concomitant short term antihormonal
treatment and either WPRT or PBRT.Until results of the RTOG 0534 trial have matured,
the role of adjuvant WPRT will remain under discussion.
So far, however, the results of this trial and the previously
published data confirm that WPRT for postoperative pros-
tate cancer is well tolerated when state-of-the-art IMRT
techniques are applied.
Conclusions
While the role of pelvic irradiation in the postoperative treat-
ment of prostate cancer remains to be fully explored, we could
demonstrate in this prospective trial that prophylactic radio-
therapy of the pelvic lymph nodes with an integrated boost to
the prostate bed can be performed without excessive toxcitiy.
Further prospective clinical trials should assess clincial efficacy
in patients with high risk of pelvic lymph node metastases.
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